All In Biotech

Drug Trial Radar · NCT05009082

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 970 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

970

Planned (sponsor's estimate)

Start

Sep 13, 2022

Primary completion

Dec 2028

Study completion Dec 2031

Sponsor

Lead sponsor
AGO Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Aug 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed by niraparib in patients with newly diagnosed advanced ovarian cancer.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Interventions

  • CarboplatinDrug

    Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles

  • PaclitaxelDrug

    175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles

  • BevacizumabDrug

    7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1

  • NiraparibDrug

    200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Assessed frequently during the trial until observation of 586 PFS events or three years after Last Patient In, whichever occurs earlier

Locations

65 sites in 1 country. Site status is shown where the registry gives one.

  • Klinikum St. Marien Amberg

    Amberg, Germany · Recruiting

  • Klinikum Augsburg

    Augsburg, Germany · Recruiting

  • Hochtaunus-Kliniken

    Bad Homburg, Germany · Recruiting

  • Helios Klinikum Berlin-Buch

    Berlin, Germany · Recruiting

  • Onkologische Schwerpunktpraxis Bielefeld

    Bielefeld, Germany · Recruiting

  • Städt. Klinikum Brandenburg

    Brandenburg an der Havel, Germany · Recruiting

  • Klinikum Bremen Mitte

    Bremen, Germany · Recruiting

  • Klinikum Chemnitz

    Chemnitz, Germany · Recruiting

  • St. Elisabeth-Krankenhaus Köln-Hohenlind

    Cologne, Germany · Recruiting

  • Klinikum Dortmund

    Dortmund, Germany · Recruiting

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Florence-Nightingale-Krankenhaus Düsseldorf

    Düsseldorf, Germany · Not yet recruiting

  • Universitätsfrauenklinik Düsseldorf

    Düsseldorf, Germany · Recruiting

  • KEM Essen | Evang. Kliniken Essen-Mitte gGmbH

    Essen, Germany · Recruiting

  • Universitätsklinikum Essen

    Essen, Germany · Recruiting

  • Klinikum Esslingen GmbH

    Esslingen am Neckar, Germany · Recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany · Recruiting

  • Klinikum Frankfurt Höchst

    Frankfurt am Main, Germany · Recruiting

  • Universitätsklinikum Gießen

    Giessen, Germany · Recruiting

  • Klinikum Gütersloh

    Gütersloh, Germany · Recruiting

  • Universitätsklinikum Halle

    Halle, Germany · Recruiting

  • Albertinen Krankenhaus

    Hamburg, Germany · Recruiting

  • Mammazentrum HH am Krankenhaus Jerusalem

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Gynäkologisch-Onkologische Praxis am Pelikanplatz

    Hanover, Germany · Recruiting

  • Universitätsklnikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Klinikum am Gesundbrunnen / SLK-Kliniken Heilbronn GmbH

    Heilbronn, Germany · Recruiting

  • Gyn.-onkolog. Gemeinschaftspraxis Hildesheim

    Hildesheim, Germany · Recruiting

  • Universtitätsklinikum Jena

    Jena, Germany · Recruiting

  • Städtisches Klinikum Karlsruhe

    Karlsruhe, Germany · Recruiting

  • ViDia Christliche Kliniken Karlsruhe

    Karlsruhe, Germany · Recruiting

  • Klinikum Kassel

    Kassel, Germany · Recruiting

  • Klinikverbund Kempten-Oberallgäu gGmbH

    Kempten, Germany · Not yet recruiting

  • Klinikum Konstanz

    Konstanz, Germany · Not yet recruiting

  • Zentrum für ambulante gynäkologische Onkologie am HELIOS Klinikum Krefeld

    Krefeld, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • St. Vincenz Krankenhaus

    Limburg, Germany · Recruiting

  • UKSH Campus Lübeck

    Lübeck, Germany · Recruiting

  • Klinikum Ludwigsburg

    Ludwigsburg, Germany · Recruiting

  • Universitätsmedizin Mainz

    Mainz, Germany · Recruiting

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.